文献速递妇科

ERAS路径对卵巢癌开腹术后麻醉药品使用的影响

Postoperative narcotic use in patients with ovarian cancer on an Enhanced Recovery After Surgery (ERAS) pathway.
PubMed 文献 · Gynecol Oncol · 2019-12-24

该回顾性队列研究比较了ERAS实施前(2014年)与实施后(2016/2018年)卵巢癌开腹手术患者的术后麻醉药品使用。结果显示ERAS组住院更短、出院前24小时及出院时处方麻醉药品更少,术后三个月内额外处方比例更低,总麻醉药品量减少55%。

要点

  • ERAS组住院时间6.7天 vs 4.2天(p=0.003),出院前24小时麻醉药品用量74.0 MME vs 25.8 MME(p=0.002)。
  • ERAS组出院时处方麻醉药品519.9 MME vs 339.7 MME(p=0.011),出院后额外处方比例52.4% vs 29.4%(p=0.012)。
  • 术后三个月内ERAS组总麻醉药品处方量1101.4 MME vs 492.1 MME(p<0.001),减少55%。

核心结论

  • 实施ERAS方案似乎可降低卵巢癌手术后三个月内患者的麻醉药品需求。

研究设计与样本

  • 回顾性队列研究,纳入2014年ERAS前42例和2016/2018年ERAS后94例卵巢癌开腹手术患者,排除长期使用麻醉药品者。

主要发现

  • ERAS组住院时间6.7天 vs 4.2天(p=0.003)。
  • ERAS组出院前24小时麻醉药品用量74.0 MME vs 25.8 MME(p=0.002)。
  • ERAS组出院时处方麻醉药品519.9 MME vs 339.7 MME(p=0.011)。
  • ERAS组出院后额外处方比例52.4% vs 29.4%(p=0.012)。
  • ERAS组术后三个月内总麻醉药品处方量1101.4 MME vs 492.1 MME(p<0.001),减少55%。

临床怎么用

  • 在卵巢癌开腹手术患者中实施ERAS路径可能有助于减少术后三个月内的麻醉药品使用。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the impact of an ERAS pathway on post-discharge narcotic use for patients with ovarian cancer undergoing open surgery. METHODS: This was a retrospective cohort study of women who underwent open ovarian cancer surgeries in 2014 prior to ERAS ("pre-ERAS") and in 2016/2018 after ERAS was instituted ("ERAS"). Patients taking chronic narcotics were excluded. A statewide prescription monitoring program was used to identify narcotic prescriptions filled in the three months after surgery. Quantity of narcotic medication is referenced in morphine milligram equivalents (MME). RESULTS: 42 pre-ERAS and 94 ERAS patients were included. The groups were similar in age, BMI, diabetes, tobacco use, mean number of prior abdominal/pelvic surgeries, and advanced stage disease. ERAS patients had a shorter hospital stay (6.7 days pre-ERAS vs 4.2 days ERAS, p = 0.003), used less narcotic in the 24 h prior to discharge (74.0 MME pre-ERAS vs 25.8 MME ERAS, p = 0.002), and filled prescriptions at time of discharge for less narcotic (519.9 MME pre-ERAS vs 339.7 MME ERAS, p = 0.011). After hospital discharge, ERAS patients filled fewer additional prescriptions (52.4% pre-ERAS, vs 29.4% ERAS, p = 0.012). In total, ERAS patients filled prescriptions for 55% fewer narcotics in the three months after surgery than the pre-ERAS group (1101.4 MME pre-ERAS vs 492.1 MME ERAS, p < 0.001). CONCLUSIONS: Institution of an ERAS protocol appears to decrease the narcotic needs of patients in the three months after ovarian cancer surgery.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kay AH, Venn M, Urban R, et al. Postoperative narcotic use in patients with ovarian cancer on an Enhanced Recovery After Surgery (ERAS) pathway. Gynecol Oncol. 2019. PMID: 31882241. doi:10.1016/j.ygyno.2019.12.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。